Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies-Reference-Cited by-同舟云学术

Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies

Published:2023-01 Issue:1 Volume:15 Page:43-52
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Yin Feng¹^ORCID,DeCiantis Chris²,Pinkas Jan¹,Das Biplab¹,Wang Frank¹,Zheng Nancy³,Hahn David³,Amrite Aniruddha¹,Adhikari Diana¹,Kane Cheikh²,Sikora Jack¹,Pittman Justin²,Wates Rebecca²,Shaheen Elizabeth¹,Harriman Shawn¹

Affiliation:

1. Pyxis Oncology, Inc., 150 Cambridgepark Drive, Cambridge, MA 02140, USA

2. KCAS Bioanalytical & Biomarker Services, 10830 South Clay Blair Boulevard, Olathe, KS 66061, USA

3. Amador Bioscience, Inc., 4695 Chabot Drive, Pleasanton, CA 94588, USA

Abstract

Aim: PYX-201 is a novel antibody–drug conjugate targeting the extra domain B splice variant of fibronectin in the tumor microenvironment. Accurate quantification of PYX-201 is critical for PYX-201 pharmacokinetics profiling in preclinical studies. Materials & methods: ELISA was performed using reference standard PYX-201, mouse monoclonal anti-monomethyl auristatin E antibody, mouse IgG1, mouse monoclonal anti-human IgG horseradish peroxidase and donkey anti-human IgG horseradish peroxidase. Results: This assay was validated at 50.0–10,000 ng/ml in rat dipotassium EDTA plasma and 250–10,000 ng/ml in monkey dipotassium EDTA plasma. Conclusion: This is the first time for a PYX-201 bioanalytical assay in any matrix to be reported.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2022-0233

Reference22 articles.

1. Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

2. ED-B fibronectin as a target for antibody-based cancer treatments

3. Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MS

4. A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B

5. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of antibody‐drug conjugates in cancer: Overview and prospects;Cancer Communications;2023-12-30

2. Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies;Journal of Pharmaceutical and Biomedical Analysis;2023-09

3. A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma;Journal of Chromatography B;2023-07

4. A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma;Bioanalysis;2023-07

5. Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach;Journal of Chromatography B;2023-05